ClinicalTrials.gg
CompletedNCT05552326Updated Oct 22, 2025

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

A Phase 3 interventional study of Olezarsen and Placebo in Severe Hypertriglyceridemia, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 205 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
446
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Hypertriglyceridemia · Ionis Pharmaceuticals, Inc..

Enrollment
4th of 12
446 · median 114
Started
2022
with 3 others
Phase 3
5 of 12
none open now
Registered
9th of 12
by date

Among the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., this one is the 4th largest by enrollment, is one of 4 that started in 2022, is one of 5 in phase 3, and was the 9th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

1 of the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

Read the detailed description

This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study in 446 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation in the study will be approximately 78 weeks, which includes an up to 12-week screening period, a 53-week treatment period, and a 13-week post-treatment evaluation period or transition to open-label extension (OLE) study with up to 1-year treatment.

03

Conditions studied

  • Severe Hypertriglyceridemia

Keywords

  • Hypertriglyceridemia
  • Hyperlipidemias
  • Metabolic Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fasting TG ≥ 500 mg/dL (5.65 mmol/L) at Screening and Qualification
  2. Participants must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to screening to minimize changes in these medications during the study.
  3. Participants must be willing to comply with diet and lifestyle recommendations as able.

Exclusion criteria

Exclusion Criteria:

  1. (HbA1c) ≥ 9.5% at Screening
  2. or aspartate aminotransferase > 3.0 ×
  3. Total > 1.5 ULN unless due to Gilbert's syndrome
  4. Estimated \< 30 mL/min/1.73 m\^2
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
446 participants (actual)

Study arms

  • Experimental
    Olezarsen

    Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.

    Drug: Olezarsen

  • Placebo comparator
    Placebo

    Olezarsen-matching placebo will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.

    Drug: Placebo

Interventions

  • Olezarsen will be administered by SC injection.

    Also known as: ISIS 678354, AKCEA-APOCIII-LRx

  • DrugPlacebo

    Olezarsen-matching placebo will be administered by SC injection.

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Fasting TG Compared to Placebo

    Time frame: Baseline and Month 6

Secondary outcomes

  1. Percent Change from Baseline in Fasting TG Compared to Placebo

    Time frame: Baseline and Month 12

  2. Percent Change from Baseline in Fasting Apolipoprotein C-III (ApoC-III), Remnant Cholesterol and Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) Compared to Placebo

    Time frame: Baseline, Month 6 and 12

  3. Proportion of Patients Who Achieve Fasting TG <500 mg/dL (5.65 mmol/L) Compared to Placebo

    Time frame: Month 12

  4. Proportion of Participants Who Achieve Fasting TG < 880 mg/dL (10 mmol/L) Compared to Placebo in the Subgroup of Participants with Baseline TG ≥ 880 mg/dL

    Time frame: Month 12

  5. Adjudicated Acute Pancreatitis Event Rate During the Treatment Period Compared to Placebo

    Time frame: Week 1 through Week 53

  6. Absolute Change in Hepatic Fat Fraction (HFF) Between Olezarsen Treatment Group and Pooled Placebo

    Time frame: Baseline through Month 12

07

Study locations

205 sites
  • Central Research Associates, Inc.
    Birmingham, Alabama 35205, United States
  • Alabama Clinical Therapeutics, LLC Alabaster
    Birmingham, Alabama 35235, United States
  • Onyx Clinical Research
    Peoria, Arizona 85381, United States
  • NRC Research Institute
    Los Angeles, California 90015, United States
  • Accel Research Sites
    DeLand, Florida 32720, United States
  • Finlay Medical Research
    Greenacres City, Florida 33467, United States
  • University of Florida Jacksonville
    Jacksonville, Florida 32209, United States
  • Meridien Research
    Maitland, Florida 32751, United States
  • Columbus Clinical Services
    Miami, Florida 33125, United States
  • Harmony Clinical Research, Inc
    North Miami Beach, Florida 33162, United States
  • Combined Research Orlando Phase I-IV
    Orlando, Florida 32807, United States
  • 3Sync Research
    Sunrise, Florida 33325, United States
  • R & B Medical Center LLC
    Tampa, Florida 33614, United States
  • JSV Clinical Research Study, Inc.
    Tampa, Florida 33634, United States
  • Metabolic Research Institute
    West Palm Beach, Florida 33401, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Accel Clinical Research
    Eatonton, Georgia 31024, United States
  • Northeast Georgia Medical Center
    Gainesville, Georgia 30501, United States
  • Randomize Now
    Newnan, Georgia 30265, United States
  • St. Vincent Medical Group
    Carmel, Indiana 46290, United States
  • University of Kansas Medical Center (KUMC)
    Kansas City, Kansas 66160, United States
  • The Research Group of Lexington, LLC
    Lexington, Kentucky 40503, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
    Louisville, Kentucky 40213, United States
  • Grace Research, LLC
    Bossier City, Louisiana 71111, United States
  • Clinical Trials of America LA, LLC
    Monroe, Louisiana 71201, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • Maryland Cardiovascular Specialists
    Baltimore, Maryland 21229, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Onyx Clinical Research
    Flint, Michigan 48532, United States
  • Onyx Clinical Research
    Rochester Hills, Michigan 48307, United States
  • Stern Cardiovascular
    Southaven, Mississippi 38671, United States
  • NYU Langone Hospital - Long Island
    Mineola, New York 11501, United States
  • Orchard Park Family Practice
    Orchard Park, New York 14127, United States
  • Clinical Trials of America, LLC
    Lenoir, North Carolina 28645, United States
  • Diabetes and Endocrinology Consultants, P.C.
    Morehead City, North Carolina 28557, United States
  • OnSite Clinical Solutions, LLC
    Salisbury, North Carolina 28144, United States
  • The Ohio State University (OSU)
    Columbus, Ohio 43203, United States
  • SV Research LLC
    Marion, Ohio 43302, United States
  • Oklahoma Heart Institute
    Tulsa, Oklahoma 74133, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Main Street Physicians Care Waterway
    Little River, South Carolina 29566, United States
  • Monument Health Clinical Research
    Rapid City, South Dakota 57701, United States
  • The Jackson Clinic
    Jackson, Tennessee 38305, United States
  • Texas Health Family Care
    Fort Worth, Texas 76107, United States
  • Vilo Research Group
    Houston, Texas 77017, United States
  • Juno Research
    Houston, Texas 77040, United States
  • Juno Research
    Houston, Texas 77054, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • Pioneer Research Solutions, Inc
    Houston, Texas 77099, United States
  • Sante Clinical Research, LLC
    Kerrville, Texas 78028, United States
  • FMC Science
    Lampasas, Texas 76550, United States
  • DCT - McAllen Primary Care, LLC
    McAllen, Texas 78503, United States
  • Texas Institute of Cardiology
    McKinney, Texas 75071, United States
  • SMS Clinical Research, LLC
    Mesquite, Texas 75149, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • Permian Research Foundation
    Odessa, Texas 79761, United States
  • Diabetes & Glandular Disease Clinic, P.A.
    San Antonio, Texas 78229, United States
  • Tranquil Research
    Webster, Texas 77598, United States
  • Aspen Clinical Research
    Orem, Utah 84058, United States
  • Ogden Clinic Grandview
    Roy, Utah 84401, United States
  • Clinical Investigation Specialists Inc.
    Kenosha, Wisconsin 53144, United States
  • CIPREC - Centro de Investigación y Prevención Cardiovascular
    Buenos Aires, C1061AAG, Argentina
  • Fundacion Favaloro
    Buenos Aires, C1093AAS, Argentina
  • Centro Médico Dra. Laura Maffei
    Buenos Aires, C1425AGC, Argentina
  • Glenny Corp SA
    Buenos Aires, C1430, Argentina
  • Instituto de Cardiología Corrientes
    Corrientes, W3400CDS, Argentina
  • Instituto Médico DAMIC
    Córdoba, X5003DCE, Argentina
  • Centro Medico San Luis
    San Luis, D5700, Argentina
  • Clínica FUSAVIM Privada
    Villa María, X5900JKA, Argentina
  • AZ Sint-Jan Brugge
    Bruges, 8000, Belgium
  • Hôpital Erasme
    Brussels, 1070, Belgium
  • Virga Jessa Hospital
    Hasselt, 3500, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • NUPEC - Nucleo de Pesquisa Clinica
    Belo Horizonte, 30220-140, Brazil
  • Núcleo de Pesquisa Clínica
    Curitiba, 80730-150, Brazil
  • Hospital Universitario Walter Cantidio - UFC
    Fortaleza, 60430-270, Brazil
  • Nucleo de Pesquisa em Cirurgia Vascular
    Porto Alegre, 90035-903, Brazil
  • IBPClin Pesquisa Clinica
    Rio de Janeiro, 20241-180, Brazil
  • CPQuali Pesquisa Clinica
    São Paulo, 01228-000, Brazil
  • Instituto do Coração - HCFMUSP
    São Paulo, 05403-000, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo - FMUSP
    São Paulo, 05403-900, Brazil
  • i9 Pesquisas Clínicas/Loema - Instituto de Pesquisas Clínica & Consultores
    São Paulo, 13092-133, Brazil
  • Medical Center Diamedical EOOD
    Dimitrovgrad, 6400, Bulgaria
  • MHAT Haskovo AD
    Haskovo, 6304, Bulgaria
  • MHAT Pazardzhik AD
    Pazardzhik, 4400, Bulgaria
  • UMHAT - Kaspela EOOD
    Plovdiv, 4000, Bulgaria
  • University Multiprofile Hospital for Active Treatment Pulmed OOD
    Plovdiv, 4000, Bulgaria
  • UMHAT Kanev AD
    Rousse, 7002, Bulgaria
  • MHAT Sliven to MMA Sofia
    Sliven, 8800, Bulgaria
  • Medical Center Smolyan Clinical Research OOD
    Smolyan, 4700, Bulgaria
  • Medical Center for Specialized Medical Help in Cardiovascular Diseases OOD
    Sofia, 1000, Bulgaria
  • Acibadem City Clinic Tokuda University Hospital
    Sofia, 1407, Bulgaria
  • Medico Dental Center ISUL Tsaritsa Yoanna EOOD
    Sofia, 1527, Bulgaria
  • Medical Centre Synexus Sofia EOOD
    Sofia, 1784, Bulgaria
  • Medical Center Zara - Med
    Stara Zagora, 6000, Bulgaria
  • DCC Equita
    Varna, 9000, Bulgaria
  • Specialized Hospital for Active Treatment of Cardiology
    Varna, 9000, Bulgaria
  • Medical Centre "Nevromedics" EOOD
    Veliko Tarnovo, 5006, Bulgaria

Showing the first 100 of 205 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Marston NA, Bergmark BA, Alexander VJ, Prohaska TA, Kang YM, Moura FA, Zimerman A, Waldman E, Weinland J, Murphy SA, Goodrich EL, Zhang S, Xia S, Li D, Goldberg AC, Goudev A, Badimon L, Kiss RG, Vrablik M, Gaudet D, Moulin P, Stroes ESG, Banach M, Cohen H, Blom D, Charng MJ, Nordestgaard BG, Nicholls SJ, Tsimikas S, Giugliano RP, Sabatine MS; CORE-TIMI 72a and CORE2-TIMI 72b Investigators. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med. 2026 Jan 29;394(5):429-441. doi: 10.1056/NEJMoa2512761. Epub 2025 Nov 8. PubMed 41211918 ↗
  • Marston NA, Bergmark BA, Alexander VJ, Karwatowska-Prokopczuk E, Kang YM, Moura FA, Prohaska TA, Zimerman A, Zhang S, Murphy SA, Tsimikas S, Giugliano RP, Sabatine MS. Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia. Am Heart J. 2025 Aug;286:125-135. doi: 10.1016/j.ahj.2025.03.003. Epub 2025 Mar 9. PubMed 40064331 ↗

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Dec 2024, 27 months.

Of 28 industry-sponsored phase 3 interventional studies under Hypertriglyceridemia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 31. This study's 27 months is above that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 18 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2022
First posted
Sep 23, 2022
StartActual
Aug 31, 2022
Primary completionActual
Dec 17, 2024
CompletionActual
Sep 12, 2025
Results delay requested
Oct 17, 2025
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05552326
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Aug 31, 2022
Primary completion
Dec 17, 2024
Completion
Sep 12, 2025
Last update
Oct 22, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olezarsen

Start the discussion